Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...
Regeneron Pharmaceuticals’ Acquisition of Checkmate Pharmaceuticals
Exscientia’s $510.4 Million IPO
Cooley LLP advised Exscientia on the deal while Goodwin Procter represented Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital...
AbCellera’s Acquisition of TetraGenetics
Goodwin Procter advised AbCellera on the deal. AbCellera (Nasdaq: ABCL) announced its acquisition of TetraGenetics. AbCellera is a technology company with a centralized operating system for next-generation...
Omega Therapeutics’ $144.6 Million IPO
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
Absci Corporation’s $200 Million Initial Public Offering
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
Rapid Micro Biosystems’ $158.4 Million IPO
Goodwin Procter advised the underwriters, while Latham & Watkins represented Rapid Micro Biosystems, Inc. in the offering. Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences...
Valo Health’s $2.8 Billion Merger with Khosla Ventures Acquisition Co.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
Centessa Pharmaceuticals’ $330 Million IPO
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model...
Privia Health Group’s $607.8 IPO
Goodwin Procter LLP advised the underwriters on the deal. Privia Health Group, Inc. (“Privia Health”) (Nasdaq: PRVA), a technology-driven, national physician enablement company that collaborates with...
Valneva SE’s $107.6 Million Global Offering
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Hogan Lovells and Cooley advised Valneva. Gide advised Goldman Sachs, Jefferies,...
Amryt Pharma’s Acquisition of Chiasma
Goodwin Procter LLP advised Chiasma, Inc. on the deal. Chiasma, Inc. (Nasdaq: CHMA) announced its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM:...
Adicet Bio, Inc.’s $137.5 Million Rights Offering
Goodwin Procter LLP advised Adicet Bio, Inc. on the deal. Adicet Bio, Inc. (Nasdaq: ACET) announced its underwritten public offering of 10,575,513 shares of its common stock,...